From a payer perspective, which of these comorbidities are relatively more important to a payer, maybe from a total cost of care perspective or even a quality metric perspective? And then how do you address that? How did this come up when you're talking about formularies and UAM and policies?

Sure.

So I think it can depend a little bit on whether the payer is government or commercial.

The answer can vary.

But some of these comorbid conditions sort of manifest themselves and have excessive expense, over 65 and others under 65 on average.

So when we see an over 65 population that's going to be borne by all of us as taxpayers through Medicare, And if it's a commercial audience or ages sort of childhood, 18 years of age and up to 65, that's going to be on the employer side or labor side.

So it's becoming more and more critical.

Friedman, to maybe talk about your experience with telemedicine and telehealth and some of the other things that you're doing in this area.